Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Symposium

[Free Online Seminar] Fighting pancreatic cancer: current treatments, pipeline landscape, and PanCAN's drug development projects


Speakers: Anne-Marie Duliege, MD, Chief Medical Officer, Pancreatic Cancer Network (PanCAN)
Organizers:
Date: 2021-12-07- 12/5/2021
Time: 11:30-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-12-06  (it will close sooner if the seating cap is reached)

About the Topic

Drug development in metastatic pancreatic ductal adenocarcinoma (PDAC) has been disappointing with a 5 year survival rate of only 10% despite considerable effort.  Precision Promise is a transformative, adaptive registration clinical trial platform that attempts to correct this by continuously and rapidly evaluating novel therapeutic options while nurturing enhanced cooperation among groups representing patient advocacy, pharmaceuticals, translational/clinical academia, and the FDA. This patient-centric study represents a fundamental shift that can substantially accelerate drug development for PDAC . PanCAN is also leading translational research by facilitating genetic testing of patients with pancreatic cancer (“Know Your Tumor” program), and has recently launched an Early Detection Initiative (EDI) in patients with recent onset diabetes.


About the Speakers

As Chief Medical Officer for the Pancreatic Cancer Action Network, Anne-Marie Duliege, MD, is responsible for the strategic direction and operational oversight for the organization’s clinical initiatives, including PanCAN’s Precision Promise℠ clinical trial.

From 2004 to 2013, Dr. Duliege was VP then CMO and Head of Research and Clinical Development at Affymax. Under her leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product for anemia in dialysis patients. Prior to that, Dr. Duliege worked at Chiron and Genentech on various programs including an HIV vaccine and treatment. Prior to her career in the biopharmaceutical industry, Dr. Duliege was an epidemiologist with the National Institute of Science and Medical Research in Paris.


2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/18/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad